Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
SOUTH SAN FRANCISCO, Calif., March 01, 2016 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8th at 8:00 AM Eastern Time at The Boston Marriott Copley Place in Boston, MA.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the clinic.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
